ABtest-MS is a new option within ABtest-Service based on mass spectrometry that allows the simultaneous determination of Aβ1-40 and Aβ1-42 from just 250 microliters of plasma.

ABtest-MS does not require enzymatic digestion or prior immunoprecipitation of the samples, substantially shortening response time and reducing costs compared to other similar assays.

Application in Clinical Trials

Due to its robustness against interferences from other plasma components, particularly anti-Aβ antibody, and variations in the pre-analytical handling of samples, ABtest-MS could be especially suitable for assisting in the recruitment and monitoring of patients in relation to clinical trials or in the context of patient care.

Advantages

Unlike other similar assays, ABtest-MS does not require prior immunoprecipitation of the sample with anti-Aβ antibodies, making it especially suitable for quantifying amyloid peptides in plasma in the context of clinical trials of immunotherapies or other anti-β-amyloid treatments.

Promising Results

ABtest-MS has already been tested in several clinical studies in which we have collaborated (BioFINDER, BioFINDER2, DPUK-Korea). The results have been published in peer-reviewed journals confirming its utility for determining the plasma Aβ42/Aβ40 ratio, with the ability to predict cerebral amyloid status and estimate disease progression.

Aβ42/Aβ40 Ratio

Determination of the Aβ42/Aβ40 ratio using ABtest-MS in a subgroup of 74 samples from patients with MCI from the phase II trial of ABvac40 (active anti-Aβ40 vaccine).

The Aβ42/Aβ40 ratio in plasma differs significantly between PET-amyloid positive and negative individuals (P<0.0001).

The Aβ42/Aβ40 ratio in plasma discriminates PET-amyloid positive and negative individuals with high accuracy (AUCROC=0.872; 0.881 for the model adjusted for ApoE genotype) and balanced sensitivity (80.4%) and specificity (94.4%).

Araclon Biotech | ABtest-MS

Our services

How can we help you?

Contact the Araclon Biotech team.

Contact us